Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +48.10%
#3 Pons Pons +21.27%
#4 Non-Playable Coin Non-Playable Coin +21.00%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +20.47%
#6 ApeX ApeX +20.21%
#7 OriginTrail OriginTrail +20.09%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.97%
#9 Zora Zora +16.31%
#10 Morpho Morpho +16.16%
Coin of the day
Smilek to the Bank Smilek to the Bank
Settings
Language
ENGLISH
Currency
USD
Theme
Beijing Biostar Pharms Co Ltd Beijing Biostar Pharms Co Ltd

Beijing Biostar Pharms Co Ltd

2563
Rank in Stocks #21402
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing... Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Share Price
$0.44774181
Last synced: 2026-08-21
Market Cap
$108.23M
Change (1 day)
2.19%
Change (1 year)
-61.12%
Country
CN
Trade Beijing Biostar Pharms Co Ltd (2563)

Category

Healthcare
Revenue for Beijing Biostar Pharms Co Ltd (2563)
Revenue in Aug 2026 TTM: 0
According to Beijing Biostar Pharms Co Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Beijing Biostar Pharms Co Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH